Idborg, Helena
Zandian, Arash
Sandberg, Ann-Sofi
Nilsson, Bo
Elvin, Kerstin
Truedsson, Lennart
Sohrabian, Azita
Rönnelid, Johan
Mo, John
Grosso, Giorgia
Kvarnström, Marika
Gunnarsson, Iva
Lehtiö, Janne
Nilsson, Peter
Svenungsson, Elisabet
Jakobsson, Per-Johan
Funding for this research was provided by:
Vetenskapsrådet (2017-02577, n/a, 2014-33867)
Stockholms Läns Landsting (20160378, n/a, ALF 20170038)
Innovative Medicines Initiative (115766)
Reumatikerförbundet (R-755861, n/a, R-73931)
The AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science (n/a)
VINNOVA (n/a)
Hjärt-Lungfonden (n/a)
Stiftelsen Konung Gustaf V:s 80-årsfond (n/a)
Åke Wiberg Stiftelse (n/a)
Alex och Eva Wallströms Stiftelse för Vetenskaplig Forskning och Utbildning (n/a)
Karolinska Institutet (n/a)
Stiftelsen Clas Groschinskys Minnesfond (n/a)
Svenska Läkaresällskapet (n/a)
Ingegerd Johansson's foundation (n/a)
Stiftelsen Apotekare Hedbergs Fond för Medicinsk Forskning (n/a)
Stiftelsen Sigurd and Elsa Goljes Minne (n/a)
Article History
Received: 3 September 2018
Accepted: 24 January 2019
First Online: 18 February 2019
Ethics approval and consent to participate
: The ethical board at the Karolinska University Hospital approved the study (reference number 03-556). All study participants gave written informed consent to participate.
: All coauthors have declared consent for publication.
: LT has consultancies for Euro Diagnostica (< $10,000), JM is employed by AstraZeneca, and JR is a member of the scientific advisory board for Phadia/Thermo Fisher. This study was supported by the AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science. Other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.